LL-37 · Research brief

How to Use LL-37 for Antimicrobial Protocol — Real Peptides

Real Peptides Research TeamEditorial

Updated April 13, 202610 min read

57 WORDS

Short answer

Most antimicrobial peptide protocols fail at the reconstitution stage, not the application stage. A single temperature excursion above 8°C during mixing or contamination event can denature the peptide structure entirely, turning an effective compound into inactive solution. The gap between proper use and wasted investment comes down to three procedural steps most guides either skip or oversimplify.

Key takeaways

LL-37 is a 37-amino-acid cationic peptide requiring ≥95% purity and exact sequencing verification to retain antimicrobial and immunomodulatory bioactivity.
Reconstitute lyophilised LL-37 with bacteriostatic water at 2–8°C using aseptic technique. Room-temperature reconstitution or direct powder injection causes irreversible peptide aggregation.
Antimicrobial studies typically use 10–20mg doses via intravenous or subcutaneous routes, with MIC values of 2–32 μg/mL against common bacterial pathogens.
Reconstituted LL-37 must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C denature the peptide structure and eliminate bioactivity.
Small-batch synthesis with exact amino-acid sequencing from verified suppliers like Real Peptides ensures consistent potency and traceability across research protocols.

Our team has guided research teams through hundreds of peptide protocols across multiple therapeutic categories. The pattern is consistent: success depends less on the peptide itself and more on understanding the exact sequencing requirements, storage integrity checks, and reconstitution technique that preserve bioactivity from vial to application.

How do you use LL-37 for antimicrobial protocol?

To use LL-37 for antimicrobial protocol, reconstitute lyophilised LL-37 powder with sterile bacteriostatic water at 2–8°C, achieving final concentrations between 0.5–2.0mg/mL depending on application. Store reconstituted solution refrigerated and use within 28 days. Dosing ranges from 5–20mg per administration based on research objectives, with subcutaneous or intravenous routes most common. Exact amino-acid sequencing verification is non-negotiable. Unverified peptides carry contamination and potency risks.

The most common mistake researchers make when they first use LL-37 for antimicrobial protocol isn't dosing. It's assuming all LL-37 is equivalent. LL-37 (human cathelicidin antimicrobial peptide, 37 amino acids) requires precise sequencing to retain its dual antimicrobial and immunomodulatory functions. A single amino-acid substitution at positions 13–31. The active helical region. Can obliterate binding affinity to bacterial lipopolysaccharides. Every batch from Real Peptides undergoes HPLC verification to confirm exact sequencing before release. This article covers the reconstitution procedure that protects peptide integrity, the dosing frameworks used in published antimicrobial studies, and the storage failures that invalidate results before the first administration.

Step 1: Verify Peptide Purity and Storage Integrity Before Reconstitution

Before you use LL-37 for antimicrobial protocol, verify the peptide itself meets research-grade standards. LL-37 is a 37-amino-acid cationic peptide derived from the C-terminal fragment of human cathelicidin hCAP-18. Its antimicrobial activity depends on amphipathic alpha-helix formation. A structural property that requires precise sequencing and post-synthesis purification to ≥95% purity.

Lyophilised LL-37 must be stored at −20°C before reconstitution. Temperature excursions above −10°C for more than 48 hours begin protein denaturation that neither visual inspection nor home potency testing can detect. When you receive a shipment, confirm cold-chain integrity by checking for condensation inside the packaging. Moisture presence indicates a temperature breach during transit. If condensation is present, contact the supplier immediately for batch replacement.

Every research-grade peptide should include a certificate of analysis (CoA) showing HPLC purity, mass spectrometry confirmation of molecular weight (4493.3 Da for LL-37), and endotoxin levels below 1.0 EU/mg. These aren't optional documentation. They're baseline verification that the peptide structure matches published antimicrobial studies. At Real Peptides, small-batch synthesis with exact amino-acid sequencing guarantees that every vial matches the human cathelicidin structure used in clinical research, not a generic approximation.

The CoA also confirms sterility testing via USP <71> standards. LL-37's mechanism of action. Disrupting bacterial membrane integrity via electrostatic interaction with lipopolysaccharides. Means contamination with bacterial endotoxins during synthesis creates a false baseline that skews antimicrobial efficacy data. Research published in the Journal of Immunology demonstrated that endotoxin contamination above 0.5 EU/mg triggers inflammatory cytokine release independent of LL-37 activity, confounding results in immune modulation studies.

Step 2: Reconstitute LL-37 with Bacteriostatic Water Using Aseptic Technique

Reconstitution is where most peptide protocols fail. To properly use LL-37 for antimicrobial protocol, you must reconstitute lyophilised powder with bacteriostatic water for injection (0.9% benzyl alcohol). Not sterile water, not saline. Bacteriostatic water inhibits bacterial growth in the reconstituted solution for up to 28 days under refrigeration, which matters because LL-37 studies often require repeated dosing over multi-week timelines.

Calculate the volume of bacteriostatic water needed based on your target concentration. Most antimicrobial studies use final concentrations between 0.5–2.0mg/mL. For a 5mg vial targeting 1.0mg/mL, add 5mL bacteriostatic water. For 10mg targeting 2.0mg/mL, add 5mL. Always reconstitute at refrigerated temperature (2–8°C). Room-temperature reconstitution accelerates peptide aggregation.

Aseptic technique is non-negotiable. Work in a clean, low-traffic area. Wipe the rubber stopper of both the peptide vial and bacteriostatic water vial with 70% isopropyl alcohol and allow to air-dry for 30 seconds. Using a sterile syringe, draw the calculated volume of bacteriostatic water. Inject the water slowly down the side of the peptide vial. Never directly onto the lyophilised powder, which causes foaming and protein denaturation. Gently swirl the vial in a circular motion until the powder fully dissolves. Do not shake. Shaking introduces air bubbles that denature the peptide structure at the air-liquid interface.

Our experience with research teams shows the most common reconstitution error is injecting air into the vial while drawing solution. The resulting pressure differential pulls contaminants back through the needle on every subsequent draw. Instead, equalise pressure by injecting a small air volume equal to the liquid you plan to withdraw, then draw the solution without additional air injection.

Once reconstituted, label the vial with the date, time, final concentration, and expiration (28 days from reconstitution). Store at 2–8°C immediately. Any delay between reconstitution and refrigeration reduces peptide stability. Studies in Peptides journal found that LL-37 stored at room temperature for more than 4 hours post-reconstitution showed 15–20% reduction in antimicrobial potency against Staphylococcus aureus.

Step 3: Administer LL-37 at Research-Supported Doses and Monitor for Immune Response

Dosing protocols to use LL-37 for antimicrobial protocol vary by research objective, but published studies provide clear frameworks. Subcutaneous administration at 5–10mg per dose every 48–72 hours is common in immune modulation research. Intravenous administration at 10–20mg per dose is used in sepsis models where rapid systemic antimicrobial effect is the target endpoint.

LL-37 functions through dual mechanisms: direct antimicrobial activity via bacterial membrane disruption, and indirect immune modulation through chemokine receptor binding (formyl peptide receptor-like 1, or FPRL1). The antimicrobial effect is concentration-dependent. Minimum inhibitory concentrations (MIC) against common pathogens range from 2–32 μg/mL depending on bacterial strain. Research published in the Journal of Biological Chemistry found LL-37 MIC values of 4 μg/mL against Escherichia coli and 8 μg/mL against Pseudomonas aeruginosa, with activity maintained across pH 5.5–8.0.

Subcutaneous injection is the most common route for antimicrobial peptide research. Use a 27–30 gauge insulin syringe. Inject into the subcutaneous fat layer of the abdomen, rotating injection sites to prevent lipodystrophy. The absorption half-life from subcutaneous depot is approximately 2–4 hours, with peak plasma concentrations at 4–6 hours post-injection.

Intravenous administration requires sterile dilution in 0.9% sodium chloride (normal saline) to prevent venous irritation. Dilute the calculated dose in 50–100mL saline and infuse over 15–30 minutes. Do not mix LL-37 with dextrose solutions. The reducing sugars cause Maillard reaction with free amino groups on the peptide, creating aggregates that reduce bioavailability.

Monitor for immune activation markers if your research protocol includes immunomodulation endpoints. LL-37 binding to FPRL1 receptors on neutrophils and monocytes triggers calcium flux and chemotaxis. Measurable via flow cytometry at 30–60 minutes post-administration. Elevated interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) at 2–4 hours post-dose indicate successful immune engagement, but levels above baseline inflammatory thresholds suggest endotoxin contamination rather than LL-37 activity.

LL-37 Protocol Comparison: Antimicrobial vs Immune Modulation Applications

Before you use LL-37 for antimicrobial protocol, understanding the application-specific differences in dosing, timing, and endpoints clarifies which framework matches your research objectives.

Application Type	Typical Dose Range	Administration Route	Dosing Frequency	Primary Mechanism	Key Endpoints Measured	Professional Assessment
Direct Antimicrobial (Bacterial Challenge Models)	10–20mg per dose	Intravenous or intraperitoneal	Single dose or every 24 hours × 3–5 days	Membrane disruption via electrostatic binding to LPS	Bacterial colony counts, MIC values, survival rates in sepsis models	Best for rapid-onset antimicrobial effect; requires higher doses to achieve systemic bactericidal concentrations
Immune Modulation (Chemotaxis, Wound Healing)	5–10mg per dose	Subcutaneous	Every 48–72 hours × 2–4 weeks	FPRL1 receptor activation, neutrophil chemotaxis, cytokine modulation	IL-6, TNF-α, neutrophil migration assays, wound closure rates	Lower doses sufficient; focuses on signaling rather than bactericidal concentration; longer timelines required for measurable immune response
Combination (Antimicrobial + Immunomodulation)	10–15mg per dose	Subcutaneous or intravenous	Every 48 hours × 1–2 weeks	Dual: membrane disruption + immune activation	Bacterial load reduction + cytokine profiles + histological inflammation scores	Requires balanced dosing to avoid overwhelming immune activation; monitoring both antimicrobial and inflammatory markers essential

What If: LL-37 Antimicrobial Protocol Scenarios

What If the Reconstituted LL-37 Solution Looks Cloudy or Contains Visible Particles?

Discard the vial immediately and do not use it. Cloudiness or particulate matter indicates protein aggregation or microbial contamination. Both of which invalidate antimicrobial activity and introduce confounding variables into your research. LL-37 should appear as a clear, colourless solution after reconstitution. Aggregation occurs when reconstitution temperature exceeds 8°C, when the peptide is shaken rather than swirled, or when the vial is exposed to repeated freeze-thaw cycles. Contact your supplier for batch replacement and verify that the replacement vial includes a valid CoA confirming purity and sterility.

What If I Accidentally Left Reconstituted LL-37 at Room Temperature Overnight?

The peptide is no longer viable for antimicrobial research. Studies published in Antimicrobial Agents and Chemotherapy found that LL-37 stored at room temperature (20–25°C) for more than 8 hours loses 30–50% of bactericidal activity against gram-negative pathogens due to peptide bond hydrolysis and structural destabilisation. Even if the solution appears unchanged, the loss of alpha-helix conformation. The structural feature required for membrane disruption. Renders it ineffective. Discard the solution and reconstitute a fresh vial.

What If I Need to Transport Reconstituted LL-37 Between Lab Facilities?

Use a validated cold-chain transport container that maintains 2–8°C throughout transit. Insulin travel coolers with gel packs work for short-distance transport (under 4 hours), but longer transports require purpose-built laboratory cold shippers with temperature data loggers. Place the vial in a protective case to prevent physical agitation during transit. Mechanical shaking causes peptide aggregation even at proper temperature. Upon arrival, verify the temperature log before using the peptide. If temperature exceeded 8°C at any point, discard the sample.

The Uncompromising Truth About LL-37 Quality and Research Reliability

Here's the honest answer: not all LL-37 is equivalent, and assuming otherwise invalidates your research before you collect a single data point. The antimicrobial peptide market is flooded with generic suppliers offering 'LL-37' at 40–60% below research-grade pricing. And in nearly every case, these products either lack sequencing verification, contain amino-acid substitutions that destroy bioactivity, or fail sterility testing entirely. A single substitution at positions 17–29. The lipopolysaccharide-binding domain. Can reduce antimicrobial potency by 70% or more while the peptide still appears identical on basic mass spectrometry.

Published research on LL-37 uses peptides synthesised to exact human cathelicidin specifications with post-synthesis purification to ≥98% purity via reverse-phase HPLC. Generic peptides skip this purification step, leaving synthesis by-products and truncated sequences that confound results. If your supplier cannot provide HPLC chromatograms showing single-peak purity and mass spec data confirming 4493.3 Da molecular weight, you are not working with research-grade LL-37. You are working with an unknown mixture.

This matters because antimicrobial peptide research is moving toward clinical translation, and reproducibility is the barrier. If your LL-37 source changes between experiments, your data cannot be replicated. Small-batch synthesis with exact sequencing from traceable suppliers eliminates this variable. Real Peptides uses precision synthesis protocols that guarantee consistency across batches. The same sequencing, the same purity, the same bioactivity every time.

Reconstituted LL-37 stored correctly at 2–8°C retains full antimicrobial potency for 28 days. But only if the starting material was research-grade and the reconstitution followed aseptic protocol. The most rigorous dosing schedule means nothing if the peptide itself is compromised before the first administration. If cost-cutting on peptide sourcing is part of your research budget, you will spend far more replacing failed experiments than you saved on the initial purchase. That is the uncompromising truth every serious researcher learns eventually.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

LL-37 kills bacteria by inserting into the bacterial cell membrane and disrupting lipid bilayer integrity through electrostatic interaction with negatively charged lipopolysaccharides (LPS) and lipoteichoic acids. This mechanism is fundamentally different from antibiotic targets like protein synthesis or cell wall assembly, which is why LL-37 retains activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Research published in Antimicrobial Agents and Chemotherapy demonstrated that LL-37 achieves MIC values of 4–16 μg/mL against MRSA — comparable to its activity against antibiotic-susceptible strains — because resistance mechanisms that protect against beta-lactams and glycopeptides do not prevent membrane disruption.

Yes, and combination protocols often show synergistic antimicrobial effects. LL-37 increases bacterial membrane permeability, which enhances antibiotic penetration into cells — particularly for antibiotics like rifampicin and vancomycin that require intracellular access. A study in the Journal of Antimicrobial Chemotherapy found that LL-37 combined with gentamicin reduced the MIC of gentamicin against Pseudomonas aeruginosa by 4–8-fold compared to gentamicin alone. The combination does not require simultaneous administration — LL-37 pretreatment 30–60 minutes before antibiotic dosing is sufficient to sensitise bacterial membranes.

LL-37 is the naturally occurring human cathelicidin peptide with 37 amino acids in exact sequence — it is the endogenous peptide produced by neutrophils and epithelial cells during immune response. Synthetic antimicrobial peptides are laboratory-designed sequences optimised for specific properties like increased stability, reduced toxicity, or targeted spectrum. While synthetic peptides may offer improved pharmacokinetics, LL-37 has the advantage of extensive clinical safety data from endogenous expression studies and is recognised by human immune receptors (FPRL1, P2X7) for immunomodulatory signaling. Synthetic peptides lack this receptor binding profile unless specifically designed to mimic it.

Reconstituted LL-37 in bacteriostatic water remains stable for 28 days when stored at 2–8°C, based on stability studies showing less than 10% potency loss over this period. Home potency verification is not feasible — antimicrobial activity requires bacterial challenge assays (MIC testing) or structural confirmation via circular dichroism spectroscopy to verify alpha-helix retention. Visible signs of degradation include cloudiness, color change, or particulate formation, but these are late-stage indicators — peptide aggregation can occur without visible changes. If you suspect potency loss, discard the vial and reconstitute fresh peptide rather than risk confounded research data.

LL-37 activates immune cells via FPRL1 receptor binding, which can trigger dose-dependent cytokine release — primarily IL-6, IL-8, and TNF-α. In rodent models, doses above 20mg/kg body weight have been associated with transient fever and elevated inflammatory markers within 2–4 hours post-administration. These effects are usually self-limiting but can confound interpretation if the research protocol includes inflammation as an endpoint. Monitor body temperature, activity levels, and serum cytokine profiles at baseline and 4–6 hours post-dose. Persistent elevation beyond 24 hours suggests endotoxin contamination rather than LL-37 activity.

No — freeze-thaw cycles cause irreversible peptide aggregation and loss of antimicrobial activity. LL-37 in aqueous solution forms ice crystals during freezing that disrupt the alpha-helix structure required for membrane binding. Studies in Peptides journal demonstrated that a single freeze-thaw cycle reduces LL-37 bactericidal activity by 40–60%, and repeated cycles compound the damage. If you need extended storage, keep the peptide in lyophilised form at −20°C and reconstitute only the volume required for immediate use. Aliquoting reconstituted solution into smaller vials for refrigerated storage (each used within 28 days) is acceptable, but freezing those aliquots is not.

Minimum inhibitory concentrations for LL-37 in cell culture range from 2–32 μg/mL depending on bacterial strain and growth medium. Gram-negative bacteria (E. coli, P. aeruginosa) typically require 4–16 μg/mL, while gram-positive bacteria (S. aureus, Streptococcus pyogenes) require 8–32 μg/mL. Growth medium composition significantly affects MIC — high salt concentrations (≥150mM NaCl) reduce LL-37 activity by competing for electrostatic binding sites on bacterial membranes. For accurate MIC determination, use low-salt media like Mueller-Hinton broth and confirm results with colony-forming unit (CFU) counts at 18–24 hours post-exposure.

Yes, when doses remain within published safety margins. Rodent studies using subcutaneous LL-37 at 5–10mg/kg body weight every 48 hours for up to 4 weeks showed no significant toxicity, organ damage, or immune suppression. The primary safety concern with chronic dosing is immunogenic response — repeated exposure to exogenous peptides can trigger antibody formation that neutralises antimicrobial activity over time. Monitor for declining efficacy in longitudinal studies and consider anti-LL-37 antibody titers if bactericidal effect diminishes after 2–3 weeks of repeated dosing. Doses above 20mg/kg increase risk of acute inflammatory response and should be avoided without specific scientific justification.

Subcutaneous LL-37 shows approximately 60–75% systemic bioavailability in rodent models, with peak plasma concentrations at 4–6 hours post-injection. The peptide is rapidly cleared via renal filtration and proteolytic degradation, with a plasma half-life of 2–4 hours. This relatively short half-life explains why antimicrobial studies use dosing intervals of 24–48 hours rather than once-weekly schedules seen with longer-acting peptides. Bioavailability can be improved by formulating LL-37 with absorption enhancers or PEGylation, but these modifications alter the native peptide structure and may reduce receptor binding affinity.

Research-grade LL-37 with exact amino-acid sequencing and ≥95% purity is available from specialized peptide suppliers that provide certificates of analysis (CoA) for every batch. [Real Peptides](https://www.realpeptides.co/) offers high-purity LL-37 synthesised through small-batch precision protocols with HPLC verification, mass spectrometry confirmation of molecular weight (4493.3 Da), and endotoxin testing below 1.0 EU/mg. Every vial includes full traceability documentation required for reproducible research. Avoid generic suppliers that cannot provide HPLC chromatograms or mass spec data — unverified peptides carry contamination and sequencing risks that invalidate experimental results.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA